Financial Markets collage Northcote Internet Logo
transparent spacer
transparent spacer Quick Search
Homepage  >  Find Company Information  > 
transparent spacer
 
curve on page transparent spacer
Northcote Internet Ltd provide Investor Relations Webcasting. Click Here 		 
transparent spacer transparent spacer transparent spacer transparent spacer
transparent spacer Home menu end curves
Newsletter
transparent spacer
transparent spacer About Us menu end curves
transparent spacer
transparent spacer Donations menu end curves
transparent spacer
transparent spacer Registrars menu end curves
transparent spacer
transparent spacer Spread Betting menu end curves
transparent spacer
transparent spacer Submit links menu end curves
transparent spacer
transparent spacer transparent spacer
transparent spacer transparent spacer transparent spacer
transparent spacer
transparent spacer
navigation curves Home navigation curves navigation curves By Index navigation curves navigation curves By Sector navigation curves navigation curves Alphabetically navigation curves navigation curves Search navigation curves navigation curves My Portfolio navigation curves
By Index > FTSE 100 > GlaxoSmithKline plc
 
Follow northcote_b on Twitter
GlaxoSmithKline plc
transparent spacer
transparent spacer
transparent spacer
Company Information
Address: 980 Great West Road
Brentford
Middlesex
TW8 9GS
 Index: FTSE 100
FTSE 350
FTSE 350 Higher Yield
FTSE All Share
FTSE TechMark All Share
FTSE Eurotop 300
Tel: 020 8047 5000 Sector: Pharmaceuticals
Fax: 020 8047 7807
E-Mail: Epic: GSK
Secretary: Simon Bicknell    
Registrar: Equiniti Ltd Updated: 10/10/2012

News from RSS Feed

Fri, 24 May 2013 09:45:00 +0000

Grant to Help Coordinate Campaign to Train One Million Community Health Workers in sub-Saharan Africa
In an effort to broadly expand the reach of health care services in sub-Saharan Africa, GlaxoSmithKline (GSK) will contribute $750,000 to the One Million Community Health Workers Campaign.
 
CR Reports
Description Report Date Published Current  
bullet point CR Report Yes  

Company Overview

GlaxoSmithKline was formed in January 2001 as the result of a merger between GlaxoWellcome and SmithKline Beecham. Headquartered in the UK and with operations based in the US, the new company is an industry leader with an estimated seven per cent of the world pharmaceutical market. Based on results, GSK had sales of £20.3 billion and profit before tax of £6.1 billion. Total pharmaceutical turnover was just over £17 billion and consumer healthcare turnover was £3.2 billion.

 
Annual Reports
Description Report Date Published Current  
bullet point Annual Report 2011 in PDF 31/12/2011 9/03/2012 Yes  
bullet point Annual Report 2010 in PDF 31/12/2010 1/03/2011 No  
bullet point Annual Report 2009 in PDF 31/12/2009 24/02/2010 No  
bullet point Annual Report 2008 in PDF 31/12/2008 3/03/2009 No  
bullet point Annual Report 2007 in PDF 31/12/2007 27/02/2008 No  
bullet point Annual Report 2006 in PDF 31/12/2006 28/02/2007 No  
bullet point Annual Report 2005 in PDF (2.75Mb) 31/12/2005 3/03/2006 No  
bullet point Annual Report 2004 in PDF 31/12/2004 4/03/2005 No  
bullet point Annual Report 2003 in PDF 31/12/2003 26/03/2004 No  
bullet point Annual Report 2002 in PDF 31/12/2002 28/03/2003 No  
bullet point Annual Report 2001 in PDF 31/12/2001 28/03/2002 No  
bullet point Annual Report 2000 in PDF 31/12/2000 12/04/2001 No  
 
Interim Reports
Description Report Date Published Current  
bullet point Interim Results 2012 in PDF 30/06/2012 25/07/2012 Yes  
bullet point Interim Results 2011 in PDF 30/06/2011 26/07/2011 No  
bullet point Interim Results 2010 in PDF 30/06/2010 21/07/2010 No  
bullet point Interim Results 2009 in PDF 30/06/2009 22/07/2009 No  
bullet point Interim Results 2002 in PDF 30/06/2002 24/07/2002 No  
bullet point Interim Results 2001 in PDF 30/06/2001 24/07/2001 No  
 
Other Links
Description
bullet point Home
bullet point Site Map
bullet point Investor Relations
bullet point Events Calendar
bullet point Press Releases
bullet point Presentations
bullet point Contacts
bullet point RSS News Feed
       
Dividend History
Type Payment Date Dividend
Interim 4/10/2012 17 p
Interim 5/07/2012 17 p
Interim 13/04/2012 5 p
Interim 12/04/2012 21 p
Interim 5/01/2012 17 p
Interim 6/10/2011 16 p
Interim 7/07/2011 16 p
Interim 7/04/2011 19 p
Interim 6/01/2011 16 p
Interim 7/10/2010 15 p
Interim 8/07/2010 15 p
Interim 8/04/2010 18 p
Interim 7/01/2010 15 p
Interim 8/10/2009 14 p
Interim 9/07/2009 14 p
Interim 9/04/2009 17 p
Interim 8/01/2009 14 p
Interim 19/10/2008 13 p
Interim 10/07/2008 13 p
Interim 10/04/2008 16 p
Interim 10/01/2008 13 p
Interim 11/10/2007 12 p
Interim 12/07/2007 12 p
Interim 12/04/2007 14 p
Interim 4/01/2007 12 p
Interim 5/10/2006 11 p
Interim 6/07/2006 11 p
Interim 6/04/2006 14 p
Interim 5/01/2006 10 p
Interim 6/10/2005 10 p
Interim 1/07/2005 10 p
Interim 7/04/2005 12 p
Interim 6/01/2005 10 p
Interim 30/09/2004 10 p
Interim 1/07/2004 10 p
Interim 15/04/2004 14 p
Interim 6/01/2004 9 p
Interim 2/10/2003 9 p
Interim 3/07/2003 9 p
Interim 17/04/2003 13 p
Interim 3/01/2003 9 p
Interim 3/10/2002 9 p
Interim 4/07/2002 9 p
Interim 18/04/2002 12 p
Interim 3/01/2002 9 p
Interim 4/10/2001 9 p
Interim 5/07/2001 9 p

News from RSS Feed

Fri, 24 May 2013 09:45:00 +0000

Grant to Help Coordinate Campaign to Train One Million Community Health Workers in sub-Saharan Africa
In an effort to broadly expand the reach of health care services in sub-Saharan Africa, GlaxoSmithKline (GSK) will contribute $750,000 to the One Million Community Health Workers Campaign.
Tue, 21 May 2013 23:15:00 +0000

GlaxoSmithKline awarded up to $200 million by U.S. government to develop new antibiotics
GlaxoSmithKline (GSK) plc and the Biomedical Advanced Research and Development Authority (BARDA), have agreed to a first of its kind collaboration that will support the development of several antibiotics to fight antibiotic resistance and bioterrorism.
Fri, 10 May 2013 16:15:00 +0000

BREO™ ELLIPTA™ gains US approval for the treatment of COPD
GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved BREO™ ELLIPTA™ as an inhaled long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
Thu, 09 May 2013 15:00:00 +0000

GSK and Save the Children form unique partnership to save the lives of one million children
An ambitious new partnership to save the lives of a million of the poorest children in the world has been launched by GSK and Save the Children.
Thu, 09 May 2013 11:30:00 +0000

GSK enters new commitment with the GAVI Alliance to supply cervical cancer vaccine for girls in the world’s poorest countries
GlaxoSmithKline (GSK) today announced a new commitment to the GAVI Alliance to supply its cervical cancer vaccine as part of a new long term programme to help protect girls against cervical cancer in the world’s poorest countries.
Tue, 07 May 2013 11:15:00 +0000

GSK gives update on plans to share detailed clinical trial data as part of its commitment to transparency
GlaxoSmithKline (GSK) today announced progress on its commitment to share more detailed data from its clinical trials.
Fri, 03 May 2013 09:10:30 +0000

Funding boost for GSK’s open innovation research into diseases affecting the developing world
GlaxoSmithKline plc (GSK) today announced a funding injection of up to £5m from the Wellcome Trust to support its open approach to discovering and developing urgently needed new treatments for diseases of the developing world.
Wed, 01 May 2013 11:30:00 +0000

Regulatory update: Trametinib US PDUFA date extended to 3 September 2013
GSK today announced that the US Prescription Drug User Fee Act (PDUFA) goal date for trametinib, its MEK inhibitor, has been extended by 3 months to 3 September 2013.
Tue, 30 Apr 2013 12:00:00 +0000

GSK announces regulatory submission for umeclidinium monotherapy in US
GlaxoSmithKline plc today announced the submission of a regulatory application in the US for the investigational once-daily medicine, umeclidinium bromide (UMEC), for patients with chronic obstructive pulmonary disease (COPD).
Mon, 29 Apr 2013 12:00:00 +0000

GlaxoSmithKline and Impax Pharmaceuticals terminate their collaboration on IPX066
GlaxoSmithKline (GSK) plc and Impax Pharmaceuticals today announced that they are terminating their collaboration for the development and commercialisation of IPX066 outside the United States and Taiwan.


transparent spacer